Are you or someone you know about to start taking Invega Sustenna? It's important to understand the dosage and how it works. This comprehensive guide offers everything patients and caregivers need to know about Invega Sustenna dosage, from understanding what it treats, the different dosages available, when it should be taken, and much more.
Invega Sustenna is an antipsychotic medication that is used to treat schizophrenia and bipolar disorder. It is a long-acting injection that is given once every four weeks.
Invega Sustenna is a long-acting injectable antipsychotic medication used to treat schizophrenia and bipolar disorder. It is available in two strengths, 150 mg and 234 mg. The usual dose for treating schizophrenia is 234 mg once monthly. The usual dose for treating bipolar disorder is 150 mg once monthly. Invega Sustenna should be injected into the buttocks (upper outer quadrant) or upper arm (deltoid muscle). The injection site should be rotated between injections to avoid skin reactions. Invega Sustenna must be refrigerated at all times, but can be kept at room temperature for up to 14 days.
Invega Sustenna is an atypical antipsychotic medication that is used to treat schizophrenia and bipolar disorder. It is available in three different dosage strengths: 37.5 mg, 75 mg, and 150 mg. The different dosage strengths are designed to be taken at different intervals, depending on the severity of the condition being treated.
The 37.5 mg dosage strength is intended for patients who are starting treatment for the first time, or for those who have not responded well to other antipsychotic medications. It is typically taken once daily, either in the morning or evening.
The 75 mg dosage strength is typically reserved for patients who have been taking lower doses of Invega Sustenna and need to increase their dose in order to achieve optimal results. It is also sometimes used as an initial dose for patients who are considered to be at a high risk for relapse. This dose is taken once daily, either in the morning or evening.
The 150 mg dosage strength is typically only prescribed to patients who have not responded well to lower doses of Invega Sustenna. It is taken once daily, either in the morning or evening.
Invega Sustenna is a long-acting injectable antipsychotic medication used to treat adults with schizophrenia. The recommended dose of Invega Sustenna is 234 mg given once monthly as an intramuscular injection. The most common side effects of Invega Sustenna include akathisia (restlessness), weight gain, and insomnia. Akathisia may be treated with medications such as propranolol or benzodiazepines. Weight gain may be treated with lifestyle changes such as diet and exercise, and medications such as metformin or topiramate. Insomnia may be treated with over-the-counter sleep aids or behavioral changes such as avoiding caffeine before bedtime.
We hope this guide has provided you with a comprehensive understanding of Invega Sustenna dosage. With knowledge and insight into the medication's various strengths, administration methods, and side effects, patients can feel more comfortable when selecting an appropriate dose to best meet their health needs. It is important for both patients and caregivers alike to take all necessary precautions with Invega Sustenna in order to avoid any unwanted complications or adverse reactions from its use.
1.
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
2.
How artificial intelligence could significantly improve the prognosis for cancer patients.
3.
Children with the "Failure to Launch" Syndrome in Adulthood Have New Hope.
4.
Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.
5.
Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.
1.
Understanding Neutrophilia: Causes, Symptoms, and Treatment Options
2.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
3.
A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology
4.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
5.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation